PMID: 26320467Sep 1, 2015Paper

Treatment with a Small Synthetic Compound, KMU-193, induces Apoptosis in A549 Human Lung Carcinoma Cells through p53 Up-Regulation

Asian Pacific Journal of Cancer Prevention : APJCP
Eun Young ChoiJong-Wook Park

Abstract

Despite recent advances in therapeutic strategies for lung cancer, mortality still is increasing. In the present study, we investigated the anti-cancer effects of KMU-193, 2-(4-Ethoxy-phenyl)-N-{5-[2-fluoro-4-(4-methyl- piperazine-1-carbonyl)-phenylamino]-1H-indazol-3-yl}-acetamide in a human non-small cell lung cancer cell line A549. KMU-193 strongly inhibited the proliferation of A549 cells, but it did not have anti-proliferative effect in other types of cancer cell lines. KMU-193 further induced apoptosis in association with activation of caspase-3 and cleavage of PLC-γ1. However, KMU-193 had no apoptotic effect in untransformed cells such as TMCK-1 and BEAS-2B. Interestingly, pretreatment with z-VAD-fmk, a pan-caspase inhibitor, strongly abrogated KMU- 193-induced apoptosis. KMU-193 treatment enhanced the expression levels of p53 and PUMA. Importantly, p53 siRNA transfection attenuated KMU-193-induced apoptosis. Collectively, these results for the first time demonstrate that KMU-193 has strong apoptotic effects on A549 cells and these are largely mediated through caspase-3- and p53-dependent pathways.

References

Jun 2, 2000·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·S S BaeP G Suh
Jul 21, 2001·Molecular Cell·K Nakano, K H Vousden
Jan 11, 2002·The New England Journal of Medicine·Joan H SchillerUNKNOWN Eastern Cooperative Oncology Group
Nov 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G V ScagliottiUNKNOWN Italian Lung Cancer Project
Jul 3, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frank FossellaChandra P Belani
Dec 10, 2003·Oncogene·Jordan S Fridman, Scott W Lowe
Mar 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George W Sledge
Jan 23, 2008·Biochemical Society Transactions·Susan E Logue, Seamus J Martin
Mar 21, 2008·Bioorganic & Medicinal Chemistry Letters·Jinho LeeSei-Hee Lee
Feb 26, 2010·Cold Spring Harbor Perspectives in Biology·Zhaohui Feng
Jul 22, 2010·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Ahmedin JemalElizabeth M Ward
Jun 7, 2011·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Yaping XuShenglin Ma
Jun 16, 2012·CA: a Cancer Journal for Clinicians·Rebecca SiegelElizabeth Ward
Jul 31, 2012·Japanese Journal of Clinical Oncology·Kumiko Saika, Ryoko Machii
Feb 19, 2013·Oncogene·A RufiniG Melino
Feb 17, 2015·Asian Pacific Journal of Cancer Prevention : APJCP·Chun-Ju LiuFu-Sheng Wan
Mar 7, 2015·Asian Pacific Journal of Cancer Prevention : APJCP·Dong-Ming WuChun-Ting Wang
Apr 10, 2015·Asian Pacific Journal of Cancer Prevention : APJCP·Qiong LiZhen-Grong Wang

❮ Previous
Next ❯

Citations

Nov 5, 2019·Toxicology Mechanisms and Methods·Ibraheem M AttafiHesham M Korashy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptotic Caspases

Apoptotic caspases belong to the protease enzyme family and are known to play an essential role in inflammation and programmed cell death. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis